JP2003119119A - Skin care preparation for anus - Google Patents
Skin care preparation for anusInfo
- Publication number
- JP2003119119A JP2003119119A JP2001314875A JP2001314875A JP2003119119A JP 2003119119 A JP2003119119 A JP 2003119119A JP 2001314875 A JP2001314875 A JP 2001314875A JP 2001314875 A JP2001314875 A JP 2001314875A JP 2003119119 A JP2003119119 A JP 2003119119A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- skin
- external preparation
- parts
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 72
- 210000000436 anus Anatomy 0.000 title claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 15
- 150000001412 amines Chemical class 0.000 claims abstract description 6
- 235000011187 glycerol Nutrition 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- -1 amine salt Chemical class 0.000 claims description 7
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 abstract description 14
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 abstract description 13
- 208000014617 hemorrhoid Diseases 0.000 abstract description 8
- 150000003839 salts Chemical class 0.000 abstract description 7
- 150000005846 sugar alcohols Polymers 0.000 abstract description 7
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 abstract description 5
- 239000003513 alkali Substances 0.000 abstract description 3
- 239000003963 antioxidant agent Substances 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract description 3
- 230000007794 irritation Effects 0.000 abstract description 3
- 239000003589 local anesthetic agent Substances 0.000 abstract description 3
- 239000003357 wound healing promoting agent Substances 0.000 abstract description 3
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 230000002439 hemostatic effect Effects 0.000 abstract description 2
- 239000008327 RUB A535 Substances 0.000 abstract 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 28
- 239000000499 gel Substances 0.000 description 17
- 238000009472 formulation Methods 0.000 description 10
- 229940031569 diisopropyl sebacate Drugs 0.000 description 9
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 9
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 7
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 230000035807 sensation Effects 0.000 description 7
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 229940035676 analgesics Drugs 0.000 description 6
- 239000000730 antalgic agent Substances 0.000 description 6
- 239000000739 antihistaminic agent Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 229940125715 antihistaminic agent Drugs 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003349 gelling agent Substances 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 229960001067 hydrocortisone acetate Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- CDULGHZNHURECF-UHFFFAOYSA-N 2,3-dimethylaniline 2,4-dimethylaniline 2,5-dimethylaniline 2,6-dimethylaniline 3,4-dimethylaniline 3,5-dimethylaniline Chemical class CC1=CC=C(N)C(C)=C1.CC1=CC=C(C)C(N)=C1.CC1=CC(C)=CC(N)=C1.CC1=CC=C(N)C=C1C.CC1=CC=CC(N)=C1C.CC1=CC=CC(C)=C1N CDULGHZNHURECF-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- FZKCAHQKNJXICB-UHFFFAOYSA-N 2,1-benzoxazole Chemical compound C1=CC=CC2=CON=C21 FZKCAHQKNJXICB-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229960001050 bupivacaine hydrochloride Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- QZUNHWGQSGFRAR-UHFFFAOYSA-N dodecyl octadecanoate;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCC QZUNHWGQSGFRAR-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- BJPJNTKRKALCPP-UHFFFAOYSA-N prilocaine hydrochloride Chemical compound [Cl-].CCC[NH2+]C(C)C(=O)NC1=CC=CC=C1C BJPJNTKRKALCPP-UHFFFAOYSA-N 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- JCQBWMAWTUBARI-UHFFFAOYSA-N tert-butyl 3-ethenylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(C=C)C1 JCQBWMAWTUBARI-UHFFFAOYSA-N 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 229940021790 tetrahydrozoline hydrochloride Drugs 0.000 description 1
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、皮膚外用剤に関
し、更に詳細には、肛門やその周囲に投与するのに好適
な皮膚外用剤に関する。TECHNICAL FIELD The present invention relates to a skin external preparation, and more particularly to a skin external preparation suitable for administration to the anus and its surroundings.
【0002】[0002]
【従来の技術】皮膚外用剤は、患部が皮膚或いは皮膚に
極めて近い部分であれば、直接患部に薬剤を投与できる
利点を有するため、皮膚或いは皮膚近傍の疾患には良く
用いられている。この様な皮膚外用剤の典型的な剤形と
しては、ローション、クリーム、軟膏、オイルゲル・ス
ティック、水性ゲルなどが挙げられる。この内、水性ゲ
ルは薬剤以外には油性成分を含有しないため、衣服など
を油性成分で汚しにくい利点がある。又、べたつきもこ
れらの製剤では最も少なく、使用感から言っても皮膚外
用剤として好ましい剤形であるといえる。この様な水性
ゲル製剤に於ける大きな問題の一つには使用時の冷感が
ある。これは水性ゲルが、水との親和性が良く、比較的
比熱の大きい水性担体を多量に用いるからである。この
為、肛門やその周囲などの神経が集中している箇所への
投与に於いては、この冷感が著しい刺激になることが少
なくない。又、かかる肛門乃至はその周囲の治療すべき
疾患が痔疾である場合には、冷感が痛感にもつながり苦
痛であるばかりではなく、投与時の冷却も又血流が滞留
している痔疾に対して好ましからぬ影響を与えると言わ
れている。この為、痔疾の治療のためには水性ゲル製剤
はあまり用いられていなかった。2. Description of the Related Art External preparations for skin are often used for diseases on or near the skin because they have the advantage of being able to directly administer the drug to the affected area if the affected area is the skin or a portion very close to the skin. Typical dosage forms of such external skin preparations include lotions, creams, ointments, oil gel sticks, aqueous gels and the like. Among them, the aqueous gel contains no oily component other than the drug, and therefore has an advantage that clothes and the like are unlikely to be soiled with the oily component. In addition, the stickiness is the smallest in these preparations, and it can be said that it is a preferable dosage form as an external preparation for skin from the viewpoint of feeling of use. One of the major problems in such an aqueous gel preparation is a cold feeling during use. This is because the aqueous gel uses a large amount of an aqueous carrier having a good affinity with water and a relatively large specific heat. Therefore, in administration to a location where nerves are concentrated, such as the anus and its surroundings, this cold sensation often causes significant stimulation. Further, when the disease to be treated in the anus or its surroundings is hemorrhoidal, not only is the cold sensation painful and painful, but also the cooling during administration causes hemorrhoidal hemorrhage. It is said to have an unfavorable effect. For this reason, aqueous gel formulations have not been used much for the treatment of hemorrhoids.
【0003】一方、1)薬剤と2)グリセリン70重量
%以上とを含有することを特徴とする、皮膚外用剤は全
く知られていなかったし、この様な皮膚外用剤が、投与
時冷感刺激や疾病の悪化要因を誘起しないことから、肛
門やその周囲への投与に好適であることも全く知られて
いなかった。On the other hand, no external preparation for skin characterized by containing 1) drug and 2) 70% by weight or more of glycerin has been known at all, and such external preparation for skin has a cold sensation upon administration. It has not been known at all that it is suitable for administration to the anus or its surroundings because it does not induce irritation or a factor that worsens the disease.
【0004】[0004]
【発明が解決しようとする課題】本発明は、この様な状
況下為されたものであり、使用時の冷感刺激を与えな
い、痔疾の治療に好適な皮膚外用剤を提供することを課
題とする。The present invention has been made under such circumstances, and it is an object of the present invention to provide a skin external preparation suitable for treating hemorrhoids, which does not give a cold sensation during use. And
【0005】[0005]
【課題の解決手段】この様な状況に鑑みて、本発明者ら
は使用時の冷感刺激を与えない、痔疾の治療に好適な皮
膚外用剤を求めて、鋭意研究努力を重ねた結果、1)薬
剤と2)グリセリン70重量%以上とを含有することを
特徴とする、皮膚外用剤がその様な性質を有しているこ
とを見出し、発明を完成させるに至った。即ち、本発明
は以下に示す技術に関するものである。
(1)1)薬剤と2)グリセリン70重量%以上とを含
有することを特徴とする、皮膚外用剤。
(2)ゲル状であることを特徴とする、(1)に記載の
皮膚外用剤。
(3)カルボキシビニルポリマーの有機アミン塩を含有
することを特徴とする、(1)又は(2)に記載の皮膚
外用剤。
(4)有機アミンがトリエタノールアミンであることを
特徴とする、(3)に記載の皮膚外用剤。
(5)実質的に水を含まないことを特徴とする、(1)
〜(4)何れか1項に記載の皮膚外用剤。
(6)肛門及び/又はその周囲に適用されることを特徴
とする、(1)〜(5)何れか1項に記載の皮膚外用
剤。
以下、本発明について更に詳細に説明を加える。In view of such a situation, the present inventors have made earnest research efforts to find a skin external preparation suitable for treating hemorrhoids, which does not give a cold sensation during use, The inventors have found that an external preparation for skin characterized by containing 1) a drug and 2) 70% by weight or more of glycerin has such properties, and completed the invention. That is, the present invention relates to the techniques described below. (1) An external preparation for skin, which comprises 1) a drug and 2) 70% by weight or more of glycerin. (2) The external preparation for skin according to (1), which is in the form of gel. (3) The external preparation for skin according to (1) or (2), which contains an organic amine salt of carboxyvinyl polymer. (4) The external preparation for skin according to (3), wherein the organic amine is triethanolamine. (5) It is characterized by containing substantially no water, (1)
(4) The external preparation for skin according to any one of (4). (6) The external preparation for skin according to any one of (1) to (5), which is applied to the anus and / or its periphery. Hereinafter, the present invention will be described in more detail.
【0006】[0006]
【発明の実施の形態】(1)本発明の皮膚外用剤が含有
する薬剤
本発明の皮膚外用剤は、1)薬剤と2)グリセリン70
重量%以上とを含有することを特徴とする。ここで、本
発明の皮膚外用剤が含有することのできる薬剤として
は、通常痔疾で使用される薬剤であれば特段の限定無く
使用することが出来、例えば、局部麻酔剤、消炎剤、鎮
痛剤、創傷治癒剤、抗酸化剤、止血剤などが好ましく例
示できる。この内、局部麻酔剤としては、アネスタミン
などのアミノ安息香酸アルキルエステル類、塩酸テトラ
カイン、塩酸ブロカインなどのアミノ安息香酸アルカミ
ンエステル類、塩酸ジブカインなどのジブカイン類、リ
ドカイン、塩酸リドカイン等のキシリジン類、塩酸オキ
シブブロカイン、塩酸ブピバカイン、塩酸メビパカイ
ン、塩酸プロピトカイン、オキシセザイン等が好適に例
示できる。これらの内ではキシリジン類が好ましく、中
でもリドカイン、塩酸リドカインが特に好ましい。消炎
剤としては、コルチゾン、酢酸コルチゾン、ヒドロコル
チゾン、酢酸ヒドロコルチゾン、塩酸テトラヒドロゾリ
ンなどの消炎ステロイド類や非ステロイド抗ヒスタミン
剤が好ましく例示できる。前記非ステロイド抗ヒスタミ
ン剤としては、ジフェンヒドラミン、塩酸ジフェンヒド
ラミンなどのエタノールアミン系抗ヒスタミン剤、マレ
イン酸クロルフェニラミン等のモノアミン系抗ヒスタミ
ン剤、プロメタジン、メキタジン等のフェノチアジン系
抗ヒスタミン剤等が好適に例示でき、中でもモノアミン
系抗ヒスタミン剤が好ましく例示でき、中でもマレイン
酸クロルフェニラミンが特に好ましい。鎮痛剤として
は、アセトアミノフェノン、フェナセチンなどのアニリ
ン系鎮痛剤、メフェナム酸、ジクロフェナクナトリウ
ム、フルフェナム酸などのアントラニール系鎮痛剤、ア
スピリン、サリチル酸コリンなどのサリチル酸系鎮痛
剤、アミノピリン、アンチピリン、スルピリンなどのピ
ラゾロン系鎮痛剤、イブプロフェン、ナプロキセン、ケ
トプロフェン、フェンブフェンなどのフェニル酢酸系鎮
痛剤が好ましく例示できる。又、抗酸化剤としては、ト
コフェロール、酢酸トコフェロール、ニコチン酸トコフ
ェロール、アスコルビン酸などが好適に例示でき、中で
もトコフェロールが特に好ましい。創傷治癒剤として
は、アラントイン等が好適に例示できる。又、殺菌消毒
剤としては、塩酸クロルヘキシジン、グルコン酸クロル
ヘキシジン、塩化ベンザルコニウムなどが好適に例示で
きる。これらの殺菌消毒剤の中では塩酸クロルヘキシジ
ンが特に好ましい。本発明の皮膚外用剤に於けるこれら
薬剤の好ましい含有量は、それぞれの薬剤について、皮
膚外用剤全量に対して、0.01〜10重量%であり、
更に好ましくは0.05〜5重量%である。BEST MODE FOR CARRYING OUT THE INVENTION (1) Drug contained in the external preparation for skin of the present invention The external preparation for skin of the present invention comprises 1) a drug and 2) glycerin 70.
It is characterized by containing more than weight%. Here, as the drug that can be contained in the external preparation for skin of the present invention, any drug that is usually used for hemorrhoids can be used without particular limitation. For example, a local anesthetic, an antiphlogistic, and an analgesic. , Wound healing agents, antioxidants, hemostatics and the like can be preferably exemplified. Among them, the local anesthetics include aminobenzoic acid alkyl esters such as anestamine, tetracaine hydrochloride, aminobenzoic acid alkamine esters such as brocaine hydrochloride, dibucaines such as dibucaine hydrochloride, lidocaine, xylidines such as lidocaine hydrochloride. Preferable examples include oxybubrocaine hydrochloride, bupivacaine hydrochloride, mebipacaine hydrochloride, propitocaine hydrochloride, and oxysezaine. Of these, xylidines are preferable, and lidocaine and lidocaine hydrochloride are particularly preferable. Preferred examples of the anti-inflammatory agent include anti-inflammatory steroids such as cortisone, cortisone acetate, hydrocortisone, hydrocortisone acetate, and tetrahydrozoline hydrochloride, and nonsteroidal antihistamines. As the nonsteroidal antihistamine, diaminehydramine, ethanolamine antihistamines such as diphenhydramine hydrochloride, monoamine antihistamines such as chlorpheniramine maleate, phenothiazine antihistamines such as promethazine and mequitazine can be preferably exemplified, and among them, monoamine antihistamines are preferable. It can be illustrated, and chlorpheniramine maleate is particularly preferable. As analgesics, acetaminophenone, aniline analgesics such as phenacetin, anthranil analgesics such as mefenamic acid, diclofenac sodium, flufenamic acid, salicylate analgesics such as aspirin, choline salicylate, aminopyrine, antipyrine, sulpiline, etc. Pyrazolone analgesics, ibuprofen, naproxen, ketoprofen, fenbufen, and other phenylacetic acid analgesics can be preferably exemplified. As the antioxidant, tocopherol, tocopherol acetate, tocopherol nicotinate, ascorbic acid and the like can be preferably exemplified, and tocopherol is particularly preferable. Suitable examples of the wound healing agent include allantoin. Suitable examples of the disinfectant include chlorhexidine hydrochloride, chlorhexidine gluconate, and benzalkonium chloride. Among these disinfectants, chlorhexidine hydrochloride is particularly preferable. The preferred content of these agents in the external preparation for skin of the present invention is 0.01 to 10% by weight with respect to the total amount of the external preparation for skin for each agent,
More preferably, it is 0.05 to 5% by weight.
【0007】(2)本発明の皮膚外用剤に含有されるグ
リセリン
本発明の皮膚外用剤は、1)薬剤と2)グリセリン70
重量%以上とを含有することを特徴とする。ここで、本
発明の皮膚外用剤が含有するグリセリンは、本発明の皮
膚外用剤を投与した場合に、皮膚表面の水分と溶媒和し
て、水和熱を発生させ、以て温感を付与する作用を有す
る。この様な効果を発揮するためには、かかるグリセリ
ンの量としては少なくとも皮膚外用剤全量に対して70
重量%が必要であり、更に好ましくは75重量%以上の
含有が例示できる。又、かかるグリセリンは水和してい
ないことが好ましく、この為には本発明の皮膚外用剤は
実質的に、水を含有しないことが好ましい。ここで、実
質的に水を含有しないとは、原料が自然に含んでしまう
キャリー・オバーは別として、水分を意志を持って配合
しないとの意味である。(2) Glycerin contained in the skin external preparation of the present invention The skin external preparation of the present invention comprises 1) a drug and 2) glycerin 70.
It is characterized by containing more than weight%. Here, the glycerin contained in the skin external preparation of the present invention, when the skin external preparation of the present invention is administered, solvates with water on the skin surface to generate heat of hydration, thereby imparting a warm feeling. Has the effect of In order to exert such effects, the amount of such glycerin is at least 70 relative to the total amount of the external preparation for skin.
A weight% is required, and a more preferable content is 75 weight% or more. Further, it is preferable that such glycerin is not hydrated. For this reason, it is preferable that the external preparation for skin of the present invention contains substantially no water. Here, "substantially free of water" means that water is not intentionally added, except for carry-over which the raw materials naturally contain.
【0008】(3)本発明の皮膚外用剤
本発明の皮膚外用剤は、1)薬剤と2)グリセリン70
重量%以上とを含有することを特徴とする。本発明の皮
膚外用剤に於いては、上記必須成分である、薬剤とグリ
セリン以外に、通常皮膚外用剤で使用される任意の成分
を含有することができる。この様な任意の成分として
は、例えば、スクワランや流動パラフィン、固形パラフ
ィンなどの炭化水素類、ジメチコンやフェメチコンなど
のシリコーン類、ホホバ油やゲイロウなどのエステル
類、ステアリン酸やオレイン酸などの脂肪酸類、ベヘニ
ルアルコールやセタノール、オレイルアルコールなどの
高級アルコール類、牛脂やオリーブオイル等のトリグリ
セライド類、ソルビタンセスキオレート、ポリオキシエ
チレンソルビタンモノオレート、ポリオキシエチレンス
テアレート等の非イオン界面活性剤、ソジウムラウリル
ステアレートなどのアニオン界面活性剤、4級アルキル
アンモニウム塩等のカチオン界面活性剤類、1,3−ブ
タンジオール、イソプレングリコール、1,2−ペンタ
ンジオールなどのグリセリン以外の多価アルコール類、
結晶セルロースや架橋型メチルポリシロキサン等の粉体
類、アクリル酸・メタクリル酸アルキルコポリマー及び
/又はその塩、カルボキシビニルポリマー及び/又はそ
の塩、キサンタンガムやヒドロキシプロピルセルロース
などの増粘剤、ビタミンやグリチルリチンなどの有効成
分などが好ましく例示できる。本発明の皮膚外用剤は、
前記の如く、水性ゲル剤であることが好ましいので、か
かるゲルを形成するゲル化剤を含有することが好まし
く、かかるゲル化剤としては、カルボキシビニルポリマ
ー及び/又はその塩が特に好ましく例示できる。カルボ
キシビニルポリマーの塩としては、塩基としてグリセリ
ンに可溶な形態のものが好ましく、具体的にはトリエタ
ノールアミンなどの有機アミンが好適に例示できる。カ
ルボキシビニルポリマー、有機アミンの好ましい含有量
は、皮膚外用剤全量に対して、0.05〜5重量%が好
ましく、更に好ましくは、0.1〜1重量%が好ましく
例示できる。又、1,3−ブタンジオール、イソプレン
グリコール、1,2−ペンタンジオールなどのグリセリ
ン以外の多価アルコール類を含有させることもこのまし
いが、多価アルコールの内、ポリエチレングリコールは
含有しないことが好ましい。グリセリン以外の多価アル
コールで好ましいものとしてはジプロピレングリコール
と1,2−ペンタンジオールが例示できる。これは、グ
リセリンの水和による熱発生を損なわないからである。
かかるグリセリン以外の多価アルコールの好ましい含有
量は、総量で10〜25重量%である。特に好ましい形
態としては、ジプロピレングリコールを10〜20重量
%、1,2−ペンタンジオールを3〜8重量%含有する
形態が好ましく例示できる。これは、この様な混合形態
に副次効果として、おいて防腐力が得られるからであ
る。本発明の皮膚外用剤は、これら必須成分と任意成分
とを常法に従って処理することにより製造することがで
きる。かくして得られた本発明の皮膚外用剤は、塗布時
に皮膚上の水分と水和し、水和熱を発生するため、塗布
時の冷感が無く、従って、痔疾などの肛門及びその周囲
の疾患に適用した場合、冷感刺激や塗布冷却による血流
の滞留を防ぐことができる。従って、本発明の皮膚外用
剤は肛門乃至はその周囲の部位に適用するのに適してい
る。(3) External preparation for skin of the present invention The external preparation for skin of the present invention comprises 1) a drug and 2) glycerin 70
It is characterized by containing more than weight%. The external preparation for skin of the present invention may contain, in addition to the above-mentioned essential components, the drug and glycerin, any component usually used in external preparations for skin. Such optional components include, for example, hydrocarbons such as squalane, liquid paraffin, and solid paraffin, silicones such as dimethicone and femethicone, esters such as jojoba oil and gay wax, and fatty acids such as stearic acid and oleic acid. , Higher alcohols such as behenyl alcohol, cetanol, oleyl alcohol, triglycerides such as beef tallow and olive oil, nonionic surfactants such as sorbitan sesquioleate, polyoxyethylene sorbitan monooleate, polyoxyethylene stearate, sodium lauryl stearate Anionic surfactants such as rate, cationic surfactants such as quaternary alkyl ammonium salts, polyhydric alcohols other than glycerin such as 1,3-butanediol, isoprene glycol and 1,2-pentanediol Kind,
Powders such as crystalline cellulose and cross-linked methyl polysiloxane, acrylic acid / alkyl methacrylate copolymer and / or its salt, carboxyvinyl polymer and / or its salt, thickeners such as xanthan gum and hydroxypropyl cellulose, vitamins and glycyrrhizin. Active ingredients such as and the like can be preferably exemplified. The external preparation for skin of the present invention is
As described above, since it is preferably an aqueous gelling agent, it is preferable to contain a gelling agent that forms such a gel. As such gelling agent, a carboxyvinyl polymer and / or a salt thereof can be particularly preferably exemplified. As the salt of the carboxyvinyl polymer, a salt soluble in glycerin as a base is preferable, and specifically, an organic amine such as triethanolamine can be preferably exemplified. The content of the carboxyvinyl polymer and the organic amine is preferably 0.05 to 5% by weight, more preferably 0.1 to 1% by weight, based on the total amount of the skin external preparation. It is also preferable that polyhydric alcohols other than glycerin such as 1,3-butanediol, isoprene glycol, and 1,2-pentanediol are contained, but polyethylene glycol is not contained in the polyhydric alcohols. preferable. Examples of preferable polyhydric alcohols other than glycerin include dipropylene glycol and 1,2-pentanediol. This is because heat generation due to hydration of glycerin is not impaired.
A preferable content of the polyhydric alcohol other than glycerin is 10 to 25% by weight in total. As a particularly preferred form, a form containing 10 to 20% by weight of dipropylene glycol and 3 to 8% by weight of 1,2-pentanediol can be preferably exemplified. This is because antisepticity can be obtained as a side effect in such a mixed form. The external preparation for skin of the present invention can be produced by treating these essential components and optional components according to a conventional method. Thus obtained external preparation for skin of the present invention is hydrated with water on the skin at the time of application and generates heat of hydration, so that there is no cooling sensation during application, and therefore diseases of the anus and its surroundings such as hemorrhoids. When applied to, it is possible to prevent cold sensation and retention of blood flow due to application cooling. Therefore, the external preparation for skin of the present invention is suitable for application to the anus or the surrounding area.
【0009】[0009]
【実施例】以下に、実施例を挙げて、本発明について更
に詳細に説明を加えるが、本発明が、かかる実施例にの
み、限定されないことは言うまでもない。EXAMPLES The present invention will be described in more detail below with reference to examples, but it goes without saying that the present invention is not limited to these examples.
【0010】<実施例1>以下に示す処方に従って、本
発明の皮膚外用剤を作成した。即ち、イ、ロの成分をそ
れぞれ80℃に加熱し、イにロを加えてゲル化させ、攪
拌冷却して本発明の水性ゲル形態の皮膚外用剤を得た。
イ
グリセリン 76.2重量部
ジプロピレングリコール 15 重量部
1,2−ペンタンジオール 5 重量部
セバシン酸ジイソプロピル 0.1重量部
塩酸リドカイン 3 重量部
カルボキシビニルポリマー 0.4重量部
ロ
トリエタノールアミン 0.3重量部<Example 1> The external preparation for skin of the present invention was prepared according to the following formulation. That is, each of the components a and b was heated to 80 ° C., the mixture b was added to a and gelled, and the mixture was stirred and cooled to obtain the aqueous gel external preparation for external use of the present invention. Iglycerin 76.2 parts by weight dipropylene glycol 15 parts by weight 1,2-pentanediol 5 parts by weight diisopropyl sebacate 0.1 parts by weight lidocaine hydrochloride 3 parts by weight carboxyvinyl polymer 0.4 parts by weight lotriethanolamine 0.3 parts by weight Department
【0011】<実施例2>ICRマウス1群10匹の肛
門を接着剤により体外に出して固定し、これにサンドペ
ーパーの擦過を行い、出血部を作成した。この出血部に
検体を綿棒で塗布し、その反応の強さにより、検体の出
血部への刺激の強さを評価した。反応の強さは、動物が
塗布時に瞬間的に移動した量として、ビデオモニターに
より測定した。検体としては、実施例1の皮膚外用剤と
実施例1の皮膚外用剤のグリセリンの内の15重量%を
ポリエチレングリコール400に置換した比較例1とを
用いた。結果を表1に示す。これより、本発明の皮膚外
用剤は出血部分に対する刺激が少ないことが明白であ
る。Example 2 Anus of 10 ICR mice per group was fixed outside the body with an adhesive and sandpaper was rubbed against the anus to create a bleeding site. The specimen was applied to this bleeding site with a cotton swab, and the strength of the reaction was used to evaluate the strength of the stimulation of the bleeding site. The intensity of the reaction was measured by a video monitor as the amount of the animals that moved instantaneously at the time of application. As the samples, the skin external preparation of Example 1 and Comparative Example 1 in which 15% by weight of glycerin of the skin external preparation of Example 1 was replaced with polyethylene glycol 400 were used. The results are shown in Table 1. From this, it is clear that the external preparation for skin of the present invention causes less irritation to the bleeding part.
【0012】[0012]
【表1】 [Table 1]
【0013】<実施例3>以下に示す処方に従って、本
発明の皮膚外用剤を作成した。即ち、イ、ロの成分をそ
れぞれ80℃に加熱し、イにロを加えてゲル化させ、攪
拌冷却して本発明の水性ゲル形態の皮膚外用剤を得た。
このものを実施例2の方法で評価したところ、平均の移
動距離は3±6cmであった。これより、グリセリン以
外の多価アルコールとしては、ジプロピレングリコール
を10〜20重量%、1,2−ペンタンジオールを3〜
8重量%含有する形態が好ましいことがわかる。
イ
グリセリン 76.2重量部
ジプロピレングリコール 5 重量部
1,2−ペンタンジオール 15 重量部
セバシン酸ジイソプロピル 0.1重量部
塩酸リドカイン 3 重量部
カルボキシビニルポリマー 0.4重量部
ロ
トリエタノールアミン 0.3重量部Example 3 The external preparation for skin of the present invention was prepared according to the following formulation. That is, each of the components a and b was heated to 80 ° C., the mixture b was added to a and gelled, and the mixture was stirred and cooled to obtain the aqueous gel external preparation for external use of the present invention.
When this was evaluated by the method of Example 2, the average movement distance was 3 ± 6 cm. From this, as a polyhydric alcohol other than glycerin, dipropylene glycol is 10 to 20% by weight, and 1,2-pentanediol is 3 to
It can be seen that the form containing 8% by weight is preferable. Iglycerin 76.2 parts by weight dipropylene glycol 5 parts by weight 1,2-pentanediol 15 parts by weight diisopropyl sebacate 0.1 parts by weight lidocaine hydrochloride 3 parts by weight carboxyvinyl polymer 0.4 parts by weight lotriethanolamine 0.3 parts by weight Department
【0014】<実施例4>以下に示す処方に従って、本
発明の皮膚外用剤を作成した。即ち、イ、ロの成分をそ
れぞれ80℃に加熱し、イにロを加えてゲル化させ、攪
拌冷却して本発明の水性ゲル形態の皮膚外用剤を得た。
このものを実施例2の方法で評価すると平均移動距離は
6±6cmであり、これより本発明の皮膚外用剤に於い
てはポリエチレングリコールを含有しないことが好まし
いことが判る。
イ
グリセリン 76.2重量部
ジプロピレングリコール 15 重量部
ポリエチレングリコール400 5 重量部
セバシン酸ジイソプロピル 0.1重量部
塩酸リドカイン 3 重量部
カルボキシビニルポリマー 0.4重量部
ロ
トリエタノールアミン 0.3重量部Example 4 The external preparation for skin of the present invention was prepared according to the following formulation. That is, each of the components a and b was heated to 80 ° C., the mixture b was added to a and gelled, and the mixture was stirred and cooled to obtain the aqueous gel external preparation for external use of the present invention.
When this product was evaluated by the method of Example 2, the average migration distance was 6 ± 6 cm, which shows that it is preferable that the external preparation for skin of the present invention does not contain polyethylene glycol. Iglycerin 76.2 parts by weight dipropylene glycol 15 parts by weight polyethylene glycol 400 5 parts by weight diisopropyl sebacate 0.1 parts by weight lidocaine hydrochloride 3 parts by weight carboxyvinyl polymer 0.4 parts by weight lotriethanolamine 0.3 parts by weight
【0015】<実施例5>以下に示す処方に従って、本
発明の皮膚外用剤を作成した。即ち、イ、ロの成分をそ
れぞれ80℃に加熱し、イにロを加えてゲル化させ、攪
拌冷却して本発明の水性ゲル形態の皮膚外用剤を得た。
このものを実施例2の評価法で評価すると、平均移動距
離は3±5cmであり、カルボキシビニルポリマーを中
和するアルカリとしては、トリエチルアミンも使用可能
であり、従って、前記アルカリとしては、有機アミンを
用いることが好ましいことが判る。
イ
グリセリン 76.2重量部
ジプロピレングリコール 15 重量部
1,2−ペンタンジオール 5 重量部
セバシン酸ジイソプロピル 0.1重量部
塩酸リドカイン 3 重量部
カルボキシビニルポリマー 0.4重量部
ロ
トリエチルアミン 0.3重量部<Example 5> The external preparation for skin of the present invention was prepared according to the following formulation. That is, each of the components a and b was heated to 80 ° C., the mixture b was added to a and gelled, and the mixture was stirred and cooled to obtain the aqueous gel external preparation for external use of the present invention.
When this is evaluated by the evaluation method of Example 2, the average migration distance is 3 ± 5 cm, and triethylamine can be used as the alkali for neutralizing the carboxyvinyl polymer. Therefore, the alkali is an organic amine. It turns out that it is preferable to use. Iglycerin 76.2 parts by weight dipropylene glycol 15 parts by weight 1,2-pentanediol 5 parts by weight diisopropyl sebacate 0.1 parts by weight lidocaine hydrochloride 3 parts by weight carboxyvinyl polymer 0.4 parts by weight rotriethylamine 0.3 parts by weight
【0016】<実施例6>以下に示す処方に従って、本
発明の皮膚外用剤を作成した。即ち、イ、ロの成分をそ
れぞれ80℃に加熱し、イにロを加えてゲル化させ、攪
拌冷却して本発明の水性ゲル形態の皮膚外用剤を得た。
このものを実施例2の評価法により評価すると、平均移
動距離は3±6であり、本発明の皮膚外用剤のゲル化剤
としてはアクリル酸・メタクリル酸(C10〜30)ア
ルキル共重合体も使用できることが判る。
イ
グリセリン 76.2重量部
ジプロピレングリコール 15 重量部
1,2−ペンタンジオール 5 重量部
セバシン酸ジイソプロピル 0.1重量部
塩酸リドカイン 3 重量部
ペムレンTR−2* 0.4重量部
ロ
トリエタノールアミン 0.3重量部
*グッドリッチ社製、アクリル酸・メタクリル酸(C10〜30)アルキル共重
合体Example 6 The external preparation for skin of the present invention was prepared according to the following formulation. That is, each of the components a and b was heated to 80 ° C., the mixture b was added to a and gelled, and the mixture was stirred and cooled to obtain the aqueous gel external preparation for external use of the present invention.
When this product was evaluated by the evaluation method of Example 2, the average migration distance was 3 ± 6. As a gelling agent for the external preparation for skin of the present invention, an acrylic acid / methacrylic acid (C10-30) alkyl copolymer was also used. It turns out that it can be used. Iglycerin 76.2 parts by weight dipropylene glycol 15 parts by weight 1,2-pentanediol 5 parts by weight diisopropyl sebacate 0.1 parts by weight lidocaine hydrochloride 3 parts by weight Pemulene TR-2 * 0.4 parts by weight lotriethanolamine 0. 3 parts by weight * Goodrich Co., acrylic acid / methacrylic acid (C10-30) alkyl copolymer
【0017】<実施例7>以下に示す処方に従って、本
発明の皮膚外用剤を作成した。即ち、イ、ロの成分をそ
れぞれ80℃に加熱し、イにロを加えてゲル化させ、攪
拌冷却して本発明の水性ゲル形態の皮膚外用剤を得た。
このものを実施例2の評価法により評価すると、平均移
動距離は3±4であり、
イ
グリセリン 78.2重量部
ジプロピレングリコール 15 重量部
1,2−ペンタンジオール 5 重量部
セバシン酸ジイソプロピル 0.1重量部
酢酸ヒドロコルチゾン 1 重量部
カルボキシビニルポリマー 0.4重量部
ロ
トリエタノールアミン 0.3重量部Example 7 The external preparation for skin of the present invention was prepared according to the following formulation. That is, each of the components a and b was heated to 80 ° C., the mixture b was added to a and gelled, and the mixture was stirred and cooled to obtain the aqueous gel external preparation for external use of the present invention.
When this product was evaluated by the evaluation method of Example 2, the average migration distance was 3 ± 4, and iglicerin 78.2 parts by weight dipropylene glycol 15 parts by weight 1,2-pentanediol 5 parts by weight diisopropyl sebacate 0. 1 part by weight Hydrocortisone acetate 1 part by weight Carboxyvinyl polymer 0.4 part by weight Lotriethanolamine 0.3 part by weight
【0018】<実施例8>以下に示す処方に従って、本
発明の皮膚外用剤を作成した。即ち、イ、ロの成分をそ
れぞれ80℃に加熱し、イにロを加えてゲル化させ、攪
拌冷却して本発明の水性ゲル形態の皮膚外用剤を得た。
このものを実施例2の評価法により評価すると、平均移
動距離は4±5であり、
イ
グリセリン 78.2重量部
ジプロピレングリコール 15 重量部
1,2−ペンタンジオール 5 重量部
セバシン酸ジイソプロピル 0.1重量部
マレイン酸クロルフェニラミン 1 重量部
カルボキシビニルポリマー 0.4重量部
ロ
トリエタノールアミン 0.3重量部Example 8 The external preparation for skin of the present invention was prepared according to the following formulation. That is, each of the components a and b was heated to 80 ° C., the mixture b was added to a and gelled, and the mixture was stirred and cooled to obtain the aqueous gel external preparation for external use of the present invention.
When this product was evaluated by the evaluation method of Example 2, the average migration distance was 4 ± 5, and iglicerin 78.2 parts by weight dipropylene glycol 15 parts by weight 1,2-pentanediol 5 parts by weight diisopropyl sebacate 0. 1 part by weight Chlorpheniramine maleate 1 part by weight Carboxyvinyl polymer 0.4 part by weight Lotriethanolamine 0.3 part by weight
【0019】<実施例9>以下に示す処方に従って、本
発明の皮膚外用剤を作成した。即ち、イ、ロの成分をそ
れぞれ80℃に加熱し、イにロを加えてゲル化させ、攪
拌冷却して本発明の水性ゲル形態の皮膚外用剤を得た。
このものを実施例2の評価法により評価すると、平均移
動距離は4±5であり、
イ
グリセリン 78.2重量部
ジプロピレングリコール 15 重量部
1,2−ペンタンジオール 5 重量部
セバシン酸ジイソプロピル 0.1重量部
アラントイン 1 重量部
カルボキシビニルポリマー 0.4重量部
ロ
トリエタノールアミン 0.3重量部Example 9 The external preparation for skin of the present invention was prepared according to the following formulation. That is, each of the components a and b was heated to 80 ° C., the mixture b was added to a and gelled, and the mixture was stirred and cooled to obtain the aqueous gel external preparation for external use of the present invention.
When this product was evaluated by the evaluation method of Example 2, the average migration distance was 4 ± 5, and iglicerin 78.2 parts by weight dipropylene glycol 15 parts by weight 1,2-pentanediol 5 parts by weight diisopropyl sebacate 0. 1 part by weight Allantoin 1 part by weight Carboxyvinyl polymer 0.4 part by weight Lotriethanolamine 0.3 part by weight
【0020】<実施例8>以下に示す処方に従って、本
発明の皮膚外用剤を作成した。即ち、イ、ロの成分をそ
れぞれ80℃に加熱し、イにロを加えてゲル化させ、攪
拌冷却して本発明の水性ゲル形態の皮膚外用剤を得た。
このものを実施例2の評価法により評価すると、平均移
動距離は3±5であり、
イ
グリセリン 77.2重量部
ジプロピレングリコール 15 重量部
1,2−ペンタンジオール 5 重量部
セバシン酸ジイソプロピル 0.1重量部
マレイン酸クロルフェニラミン 0.2重量部
酢酸ヒドロコルチゾン 0.5重量部
酢酸テトラヒドロゾリン 0.05重量部
アラントイン 1 重量部
塩酸クロルヘキシジン 0.25重量部
カルボキシビニルポリマー 0.4重量部
ロ
トリエタノールアミン 0.3重量部<Example 8> An external preparation for skin of the present invention was prepared according to the following formulation. That is, each of the components a and b was heated to 80 ° C., the mixture b was added to a and gelled, and the mixture was stirred and cooled to obtain the aqueous gel external preparation for external use of the present invention.
When this product was evaluated by the evaluation method of Example 2, the average migration distance was 3 ± 5, and iglicerin 77.2 parts by weight dipropylene glycol 15 parts by weight 1,2-pentanediol 5 parts by weight diisopropyl sebacate 0. 1 part by weight Chlorpheniramine maleate 0.2 parts by weight Hydrocortisone acetate 0.5 parts by weight Tetrahydrozoline acetate 0.05 parts by weight Allantoin 1 part by weight Chlorhexidine hydrochloride 0.25 parts by weight Carboxyvinyl polymer 0.4 parts by weight Lotriethanolamine 0 .3 parts by weight
【0021】[0021]
【発明の効果】本発明によれば、使用時の冷感刺激を与
えない、痔疾の治療に好適な皮膚外用剤を提供すること
ができる。According to the present invention, it is possible to provide a skin external preparation suitable for treating hemorrhoids that does not give a cold sensation during use.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 杉山 清治 神奈川県横浜市神奈川区高島台27番地1 ポーラ化成工業株式会社横浜研究所内 Fターム(参考) 4C076 AA09 BB29 CC01 DD38W DD47 DD50Z EE09A EE23 FF35 FF56 FF61 ─────────────────────────────────────────────────── ─── Continued front page (72) Inventor Seiji Sugiyama 27-1 Takashimadai, Kanagawa-ku, Yokohama-shi, Kanagawa Pola Kasei Co., Ltd. Yokohama Research Center F term (reference) 4C076 AA09 BB29 CC01 DD38W DD47 DD50Z EE09A EE23 FF35 FF56 FF61
Claims (6)
上とを含有することを特徴とする、皮膚外用剤。1. An external preparation for skin, which comprises 1) a drug and 2) 70% by weight or more of glycerin.
1に記載の皮膚外用剤。2. The external preparation for skin according to claim 1, which is in the form of gel.
塩を含有することを特徴とする、請求項1又は2に記載
の皮膚外用剤。3. The external preparation for skin according to claim 1, which contains an organic amine salt of carboxyvinyl polymer.
ることを特徴とする、請求項3に記載の皮膚外用剤。4. The external preparation for skin according to claim 3, wherein the organic amine is triethanolamine.
る、請求項1〜4何れか1項に記載の皮膚外用剤。5. The external preparation for skin according to any one of claims 1 to 4, which is substantially free of water.
とを特徴とする、請求項1〜5何れか1項に記載の皮膚
外用剤。6. The external preparation for skin according to any one of claims 1 to 5, which is applied to the anus and / or its periphery.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001314875A JP4194264B2 (en) | 2001-10-12 | 2001-10-12 | Anal skin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001314875A JP4194264B2 (en) | 2001-10-12 | 2001-10-12 | Anal skin preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003119119A true JP2003119119A (en) | 2003-04-23 |
| JP4194264B2 JP4194264B2 (en) | 2008-12-10 |
Family
ID=19133121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001314875A Expired - Fee Related JP4194264B2 (en) | 2001-10-12 | 2001-10-12 | Anal skin preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4194264B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005020960A1 (en) * | 2003-08-29 | 2005-03-10 | Sato Pharmaceutical Co., Ltd. | Preparation for rectal administration |
| JP2007291073A (en) * | 2006-03-31 | 2007-11-08 | Daiichi Sankyo Healthcare Co Ltd | Nebulization pharmaceutical formulation for hemorrhoid |
| JP2013056843A (en) * | 2011-09-08 | 2013-03-28 | Taisho Pharmaceutical Co Ltd | Topical steroidal anti-inflammatory external preparation |
-
2001
- 2001-10-12 JP JP2001314875A patent/JP4194264B2/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005020960A1 (en) * | 2003-08-29 | 2005-03-10 | Sato Pharmaceutical Co., Ltd. | Preparation for rectal administration |
| JPWO2005020960A1 (en) * | 2003-08-29 | 2007-11-01 | 佐藤製薬株式会社 | Formulation for rectal administration |
| JP2007291073A (en) * | 2006-03-31 | 2007-11-08 | Daiichi Sankyo Healthcare Co Ltd | Nebulization pharmaceutical formulation for hemorrhoid |
| JP2013056843A (en) * | 2011-09-08 | 2013-03-28 | Taisho Pharmaceutical Co Ltd | Topical steroidal anti-inflammatory external preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4194264B2 (en) | 2008-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101035509B (en) | Organogel formulations for therapeutic use | |
| CA2567575C (en) | Organo-gel formulations for therapeutic applications | |
| RU2754846C1 (en) | Local anaesthetic compositions | |
| WO2019014380A1 (en) | Platforms for topical delivery of medicaments and methods for their preparation | |
| JPH07504657A (en) | Topical fragrance releasing composition | |
| JP2013515002A5 (en) | ||
| JP2014503586A (en) | Oil composition | |
| JP2006528680A (en) | Alcohol-free transdermal analgesic composition and process and use thereof | |
| US11000495B2 (en) | Topical diclofenac sodium compositions | |
| EA011244B1 (en) | Novel compositions for topical delivery | |
| JP2000327557A (en) | Emulsion composition | |
| JP2003095985A (en) | Blood circulation promoting composition | |
| JP5667052B2 (en) | Transdermal pharmaceutical composition containing danazol | |
| JPH09110680A (en) | Dermatitis-curing strap | |
| JP4256125B2 (en) | Composition for external use | |
| JP4813725B2 (en) | Antipruritic topical agent | |
| JP2012092067A (en) | Nonsteroidal anti-inflammatory analgesic agent for external use | |
| JP7299683B2 (en) | Skin topical composition | |
| JP2004026721A (en) | Hot external preparation composition | |
| JP2003119119A (en) | Skin care preparation for anus | |
| JP2002356430A (en) | External preparation for skin containing prednisolone valerate acetate and antihistamine | |
| JP4124495B2 (en) | Local anesthetic composition | |
| JP4791682B2 (en) | Acupuncture treatment | |
| JPH1180031A (en) | External preparations and methods for enhancing transdermal or transmucosal absorption | |
| JPS63230641A (en) | Transcutaneous absorbefacient and external drug for skin containing said absorbefacient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040823 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080523 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080613 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080916 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080922 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141003 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |